Navigation Links
CSA Medical, Inc. Appoints President
Date:9/30/2008

BALTIMORE, Sept. 30 /PRNewswire/ -- CSA Medical, Inc. announced today the promotion of Steven E. Schaefer to President of CSA Medical, Inc. Steve Schaefer, Chief Financial Officer since November 2006, has been appointed President of CSA Medical, Inc. The Company, headquartered in Baltimore, Maryland, is the world's exclusive provider of a ground-breaking, therapeutic medical device. The device allows physicians to use endoscopes to quickly and easily spray supercool (-196 degrees C) liquid nitrogen onto unwanted tissues deep inside the body. Mr. Schaefer's additional responsibilities for the growth and operations of the company will allow company CEO and Board Chairman Tim Askew to expand the patented platform technology into additional treatment areas. "Steve will focus his efforts on expanding the early success of the GI business of CSA Medical," said Askew. He continued, "Over the past two years he has demonstrated a great capacity to drive visionary growth and has my confidence in taking the business to the next level."

(Photo: http://www.newscom.com/cgi-bin/prnh/20080930/NETU087 )

(Logo: http://www.newscom.com/cgi-bin/prnh/20080721/NEM114LOGO )

CSA Medical has seen impressive growth since commercially launching the CryoSpray product in May 2007. During this time Mr. Schaefer has worked closely with VP of Sales and Marketing, Ric Hughen, to launch and expand sales of CSA Medical's device. In the first year of commercial availability the FDA-cleared technology has been adopted nationwide in over fifty top healthcare institutions and the pace of adoption is continuing to accelerate. "I am committed to drive CSA Medical and its fight against GI diseases to new levels while growing and protecting the remarkable culture of our organization," said Mr. Schaefer.

Steve Schaefer joined CSA Medical, Inc. with a background in finance, marketing, business development and sales leadership. A Certified Public Accountant, and Drexel University graduate, Steve previously has served in executive roles at several high-growth technology companies including RewardsPlus and FiberTech Medical.

About CSA Medical: CSA Medical, Inc is the manufacturer of the CryoSpray Ablation(TM) System. The CSA System utilizes a patented spray cryogenic technology that allows a physician to safely and effectively destroy a wide range of unwanted tissues via an endoscope.

For more information, please contact Richard Hughen at rhughen@csamedical.com.


'/>"/>
SOURCE CSA Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
4. Thermage, Inc. Announces Distribution Agreement With Eclipse Medical, Ltd.
5. Medical, Behavioral Woes Can Drive Dogs to Bite
6. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
7. Sedgwick CMS and UnitedHealth Group to Develop Integrated Disability, Medical, Workers Compensation and Leave Administration Services for Employers
8. Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome
9. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
10. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
11. Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty discusses ... with the help of a weight loss surgery. The woman, declaring “I will not hate ... been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while it ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its new partnership with the Home Care Association of America (HCAOA). This agreement ... Private Duty Accreditation services, as well as discounts on Accreditation University (AU) educational ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage ... unmet medical needs, today announced that it will ... development program, based on its proprietary self-delivering RNAi ... (SID) 76 th Annual Meeting.  The SID ... relevant to skin health and disease through education, ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: